<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368336">
  <stage>Registered</stage>
  <submitdate>9/04/2015</submitdate>
  <approvaldate>28/04/2015</approvaldate>
  <actrnumber>ACTRN12615000394549</actrnumber>
  <trial_identification>
    <studytitle>Renal Replacement Therapy Intensity in Severe Acute Kidney Injury: An Individual Patient Data Meta-analysis of Randomized Trials </studytitle>
    <scientifictitle>Renal Replacement Therapy Intensity in Severe Acute Kidney Injury and  its Effect on All-cause Mortality and Recovery to Dialysis Independence: An Individual Patient Data Meta-analysis of Randomized Trials </scientifictitle>
    <utrn />
    <trialacronym>IMPROVE-AKI study</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe acute kidney injury requiring renal replacement therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Higher intensity haemodialysis, a prescribed dose of 35 to 48 ml/kg/h or defined as published in the original publications</interventions>
    <comparator>Standard intensity haemodialysis, a prescribed dose of 20 to 25 ml/kg/h or defined as published in the original publications</comparator>
    <control>Dose comparison</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause mortality </outcome>
      <timepoint>At trial specific follow-up time points. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Renal replacement therapy (RRT) dependence, defined as the proportion of patients who were still RRT dependent at 7, 14, 28, 60 and 90 days, time to recovery to RRT independence </outcome>
      <timepoint>At trial specific follow-up time points</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All randomized controlled trials assessing the effects of different doses of renal replacement therapy (RRT) in patients with AKI.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with chronic kidney disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Individual patient data meta-analysis. Individual patient data from each eligible trial was pooled and all the outcomes were analyzed based on the intention to treat principle, taking all randomized participants into consideration. The effect of different dialysis dosing intensities upon mortality and dialysis outcomes was analyzed using log-binomial regression with a random effects model and random study-by-treatment interaction.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>9/04/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>3600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Enrolling by invitation</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>The George Institute for Global Health</primarysponsorname>
    <primarysponsoraddress>Level 10, King George V Building, Royal Prince Alfred Hospital, Missenden Rd, Camperdown NSW 2050 Australia  </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian National Health and Medical Research Council (NHMRC) project grant</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Renal replacement (RRT) dose intensity may affect patient and kidney outcomes in severe acute kidney injury (AKI) but randomized controlled trial (RCTs) have been contradictory for mortality and inadequately powered for renal outcomes. The Investigation, Management, Prognosis, Recovery, Observation, Value and Evaluation of Acute Kidney Injury (IMPROVE-AKI) collaboration brings together investigators from current randomised clinical trials of RRT dose intensity in AKI to perform IPDMA of the effects of RRT dose intensity.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NSW Population and Health Services Research Ethics Committee </ethicname>
      <ethicaddress>73 Miller Street
North Sydney NSW 2060
Australia 
</ethicaddress>
      <ethicapprovaldate>15/04/2011</ethicapprovaldate>
      <hrec>LNR2011/004</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368336-IPD%20Renal%20SAP%20v2%2010Apr12[2].docx</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Rinaldo Bellomo</name>
      <address>10-12 Ievers Terrace, Carlton VIC 3053
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia</address>
      <phone>61-3-9496 5992</phone>
      <fax />
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Rinaldo Bellomo</name>
      <address>10-12 Ievers Terrace, Carlton VIC 3053,
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia</address>
      <phone>61-3-9496 5992</phone>
      <fax />
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Rinaldo Bellomo</name>
      <address>10-12 Ievers Terrace, Carlton VIC 3053,
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia</address>
      <phone>61-3-9496 5992</phone>
      <fax />
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amanda Y Wang</name>
      <address>Renal and Metabolic Division, The George Institute for Global Health</address>
      <phone>61-2-99934573</phone>
      <fax />
      <email>awang@georgeinstitute.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>